SELDI-TOF serum proteomics and breast cancer: which perspective?

Vito Michele Garrisi1, Ines Abbate, Michele Quaranta

  • 1Chemical-Clinical Microbiology and Immunology Laboratory Unit, 'Giovanni Paolo II', National Cancer Institute, Via Samuel F. Hahnemann 10, 70126 Bari, Italy. vmgarrisi@libero.it

Expert Review of Proteomics
|December 18, 2008
PubMed
Summary

Clinicians need better breast cancer biomarkers. Proteomic profiling using SELDI-TOF mass spectrometry shows promise for identifying new serum markers for early diagnosis and improved patient outcomes.